Debiganto 75mg Tablet

Debiganto 75mg Tablet is an anticoagulant or blood thinner. It helps prevent and treat blood clots. It is used to reduce the risk of stroke and heart attack. It prevents and treats clot formation in the veins of your legs, lungs, brain, and heart.

Debiganto 75mg Tablet is commonly used in patients with irregular heart rhythm (atrial fibrillation) to prevent clot formation. It also reduces the risk of getting clots in people who have undergone knee or hip replacement surgeries. It can be taken with or without food, but it is best to take them at the same time each day. You may need to take this medicine for many years, even for life in some cases. Do not stop taking it or change the dose without guidance from your doctor. It could quickly put you more at risk of having a heart attack, stroke, or thrombosis (formation of a blood clot within a blood vessel). You can reduce your risk of having a blood clot by making changes to your lifestyle, such as not smoking, eating a healthy diet, getting regular exercise, and losing weight if you need to.

The most common side effect of Debiganto 75mg Tablet are stomach upset and bleeding more easily than normal, for example having nosebleeds or bruising. If you experience any symptoms, tell your doctor immediately. Other side effects include headaches, seizures, allergic reactions, changes to your eyesight, and tiredness.

Do not take this medicine if you have severe kidney or liver problems, if you are currently bleeding or if you are taking other medicines to reduce blood clotting. You should not breastfeed while using this medicine. Unlike other anticoagulants, a regular blood test (PT-INR) is not required while taking this medicine.

• Treatment and prevention of Blood clots

Treatment and prevention of Blood clots
Debiganto 75mg Tablet is a type of medicine known as an anticoagulant. Although it does not “dissolve” blood clots, it can prevent them from getting bigger so your body can dissolve them over time. It will also prevent new ones from forming. It works by blocking a substance in the body which is involved in blood clotting. This keeps your blood flowing freely around your body and makes it less likely that a clot will form inside a blood vessel. This can help prevent or reduce damage caused by stroke, clots in your lungs (pulmonary embolism), or other blood vessels (thrombosis). It can also make it less likely that parts of a clot will break off and travel to other parts of the body. You should take it regularly and make appropriate lifestyle changes to help this medicine be effective.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Dbgron

• Nausea
• Anemia (low number of red blood cells)
• Gastrointestinal bleeding
• Dyspepsia
• Diarrhea
• Abdominal pain
• Nosebleeds
• Skin bleeding

Take this medicine in the dose and duration as advised by your doctor. Debiganto 75mg Tablet may be taken with or without food, but it is better to take it at a fixed time.

Debiganto 75mg Tablet is a novel oral anticoagulant (NOAC). It works by preventing the formation of blood clots in the body.

• Take it as per dose and duration suggested by your doctor.

• Debiganto 75mg Tablet increases your risk of bleeding. Be careful while shaving, cutting fingernails or toenails, using sharp objects or engaging in contact sports (e.g., football and wrestling).

• If you are going to have a surgery or dental treatment, you may be asked to stop taking Debiganto 75mg Tablet temporarily.

• Your doctor may get a blood test done to check kidney function before starting treatment with this medicine.

• Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.

• Do not stop taking the medication without talking to your doctor.

Weitz JI. Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 865-66.

Zehnder JL. Drugs Used in Disorders of Coagulation. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 594.

Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 346-47.

Fox KA, White HD, Gersh BJ, et al. Antithrombotic Agents: Platelete Inhibitors, Acute Anticoagulants, Fibrinolytics, and Chronic Anticoagulants. In: Opie LH, Gersh BJ, editors. Drugs for the Heart. 8th ed. Philadelphia, Pennsylvania: Elsevier Saunders; 2013. pp. 363-65.

Dabigatran etexilate mesylate. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals, Inc.; 2010 [revised Nov. 2015]. [Accessed 15 Mar. 2019] (online) Available from:

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Dabigatran. [Updated 2020 Jan 20]. [Accessed 19 Feb. 2020] (online) Available from:

Central Drugs Standard Control Organisation (CDSCO). Dabigatran Etexilate. [Accessed 15 Mar. 2019] (online) Available from: